Machine Learning Model for Cognitive Impairment Progression Prediction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The variability in progression of cognitive impairment among patients with neurological diseases limits decision-making and treatment planning, and conventional methods for detecting brain amyloid status are invasive and impractical for widespread screening.

Innovation Solution

Development of predictive models trained using clinical trial data to forecast cognitive impairment progression and brain amyloid status, utilizing baseline data including demographic, cognitive, imaging, and biomarker information, allowing for personalized care and patient selection for clinical trials.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional methods (PET scan with radioactive tracer) are used to detect brain amyloid status, then measurement precision is improved, but device complexity and ease of operation deteriorate

Engineering Contradiction:
Improvebrain amyloid status detection accuracyVSAvoidimaging procedure complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent uses machine learning models to create a computational copy of the PET scan detection process. The model is trained on PET scan data and then uses simpler input data (cognitive assessments, demographic information, basic biomarkers) to predict brain amyloid status, effectively copying the diagnostic capability without requiring the complex imaging procedure

Inventive Principle:
Principle #26Copying

Solution Approach 2:

The patent introduces machine learning models as an intermediary between simple baseline measurements and brain amyloid status detection. The model acts as a mediator that translates easily obtained baseline data into predictions of cognitive impairment progression and amyloid status, avoiding the need for direct complex imaging

Inventive Principle:
Principle #24Intermediary (Mediator)

2Measurement precision

If conventional methods (PET scan with radioactive tracer) are used to detect brain amyloid status, then measurement precision is improved, but ease of operation deteriorates

Engineering Contradiction:
Improvebrain amyloid status detection accuracyVSAvoidscreening accessibility
Core Design Contradiction:
Measurement precisionVSEase of operation

Solution Approach 1:

The machine learning model copies the diagnostic function of PET scans using easily obtainable data. By training the model on comprehensive datasets including PET scan results, it learns to predict amyloid status from simple baseline measurements, making screening as easy as administering cognitive assessments and collecting demographic information

Inventive Principle:
Principle #26Copying

Solution Approach 2:

The patent replaces expensive, complex PET scanning with inexpensive, simple baseline assessments. The model uses readily available data (cognitive tests, demographic information, basic biomarkers) that can be obtained quickly and cheaply, making widespread screening economically feasible

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Reliability

If larger control groups are used in clinical trials to account for progression variance, then reliability is improved, but productivity deteriorates

Engineering Contradiction:
Improveclinical trial statistical powerVSAvoidtrial enrollment efficiency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies preliminary action by using machine learning models to predict which subjects are most likely to show cognitive impairment progression before the clinical trial begins. This pre-screening allows researchers to select subjects with higher predicted progression rates, increasing the reliability of trial results without needing larger sample sizes

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent applies local quality by using the machine learning model to identify and select specific subsets of subjects (those with predicted high progression) rather than treating all subjects uniformly. This targeted selection enriches the trial population with subjects most likely to show treatment effects, improving statistical power while reducing overall sample size requirements

Inventive Principle:
Principle #3Local quality

Data Source

PatentUS20250022603A1Predicting progression of cognitive impairment
Publication Date: 2025.01.16 EISAI R&D MANAGEMENT CO LTD
  • US20250022603A1 patent drawing
  • US20250022603A1 patent drawing
  • US20250022603A1 patent drawing

AI summary

A platform is disclosed for the training and deployment of statistical or machine-learning models for predicting the progression of cognitive impairment or brain amyloid status. The statistical or machine-learning models can be trained to predict the progression of cognitive impairment or brain amyloid status using baseline image data, biomarker data, genomic data, demographic data, cognitive data, or the like. The platform can be configured to obtain training data, train the statistical or machine-learning models, and support using the trained statistical or machine-learning models to respond to prediction requests.